Accuracy assessment of a potential clinical use of navigation-guided intra-operative liver metastasis brachytherapy—a planning study
For patients with inoperable liver metastases, intra-operative liver high dose-rate brachytherapy (HDR-BT) is a promising technology enabling delivery of a high radiation dose to the tumor, while sparing healthy tissue. Liver brachytherapy has been described in the literature as safe and effective for the treatment of primary or secondary hepatic malignancies. It is preferred over other ablative techniques for lesions that are either larger than 4 cm or located in close proximity to large vessels or the common bile duct. In contrast to external beam radiation techniques, organ movements do not affect the size of the irradiated volume in intra-operative HDR-BT and new technical solutions exist to support image guidance for intra-operative HDR-BT. We have retrospectively analyzed anonymized CT datasets of 5 patients who underwent open liver surgery (resection and/or ablation) in order to test whether the accuracy of a new image-guidance method specifically adapted for intra-operative HDR-BT is high enough to use it in similar situations and whether patients could potentially benefit from navigation-guided intra-operative needle placement for liver HDR-BT.
KeywordsLiver Brachytherapy Image guidance Radiotherapy Liver metastases
Genauigkeitsabschätzung einer möglichen klinischen Anwendung der navigationsgestützten intraoperativen Lebermetastasen-Brachytherapie – Eine Planungsstudie
Für Patienten mit inoperablen Lebermetastasen ist die intraoperative Hochdosis-Brachytherapie (HDR-BT) eine vielversprechende Technologie, die es ermöglicht, eine hohe Strahlendosis auf den Tumor zu liefern, während das umliegende gesunde Gewebe geschont wird. Die Leber-BT wurde in der Literatur als sicher und wirksam für die Behandlung von primären oder sekundären Tumoren in der Leber beschrieben. Sie ist für Läsionen mit einer Größe > 4 cm oder in unmittelbarer Nähe zu großen Gefäßen sowie in engem Kontakt mit dem zentralen Gallengang gegenüber anderen ablativen Verfahren zu bevorzugen. Im Gegensatz zu den externen Strahlentherapietechniken wirken sich bei der intraoperativen HDR-BT Organbewegungen nicht auf die Größe des bestrahlten Volumens aus. Neue bildgestützte technische Lösungen existieren, um die intraoperative Applikatoreinlage für die HDR-BT zu unterstützen. Wir haben retrospektiv anonymisierte Computertomographiedatensätze von 5 Patienten analysiert, welche eine offene Leberoperation erhalten haben (Resektion und/oder Ablation). Hierbei testeten wir, ob die Genauigkeit der speziell für die intraoperative HDR-BT angepasste Navigation ausreicht, um sie in vergleichbaren Situationen anzuwenden, und ob Patienten möglicherweise von der neuen Bildführungsmethode zur intraoperativen Nadelplatzierung bei der Leber-HDR-BT profitieren könnten.
SchlüsselwörterLeber Brachytherapie Bildführung Radiotherapie Lebermetastasen
Colorectal cancer (CRC) is the most frequent primary site to give rise to metastatic liver disease. The role of local therapy has been most thoroughly evaluated in CRC hepatic metastases . Surgical resection has become the preferred treatment for these patients, since it can provide cure of disease and is associated with 5‑year survival rates in the range of 25–47% [2, 3, 4, 5]. However, due to associated co-morbidities, non-resectable extrahepatic disease, or multiple liver lesions with inadequate residual functioning liver parenchyma after surgery, 70–80% of patients with colorectal liver metastases are not candidates for resection . This has encouraged the use of alternative surgical approaches, such as radiofrequency and microwave tumor ablation, as well as cryotherapy and other ablative techniques . For small tumors, radiofrequency ablation (RF) or microwave ablation (MWA) achieve excellent local control . However, high local recurrence rates of up to 39% , particularly in tumors > 3 cm and tumors adjacent to large vessels [8, 10], remain a challenge. There is growing interest in applying radiotherapy to hepatic malignancies. A decade ago, image-guided high dose-rate brachytherapy (HDR-BT) of liver tumors was introduced  as a local radio-ablative technique, in which an iridium-192 source is temporarily inserted into the tumor through catheters placed under image guidance . HDR-BT is preferred over other thermal ablative techniques for lesions > 4 cm in size or located near large vessels as well as those in close contact with the central bile duct [13, 14, 33, 34]. Any HDR-BT intervention within the liver requires an in-depth three-dimensional (3D) understanding of the organ’s internal vascular and biliary anatomy. To optimize the treatment outcomes, it is important that these procedures result in accurate positioning of the needle to achieve complete tumor dose coverage and minimize the probability of damage to surrounding normal tissue. Moreover, there might be organs at risk (OAR)—such as the hepatic arteries, portal veins, and bile ducts—in the proximity of the needle path that imperatively should not be touched. For surgical interventions, the introduction of pre-operative 3D imaging data from computer tomography (CT) or magnetic resonance imaging (MRI) in the early 1990s enabled surgeons to virtually plan and evaluate surgical strategies prior to the actual surgery using the available imaging data . Clinically applicable surgical planning solutions are nowadays available . Computer-assisted open liver surgery has now been available for 10 years, but only recently were image guidance systems specifically optimized for hepatopancreaticobiliary (HPB) surgery [15, 38]. The missing link between virtual surgery planning and pre-operative evaluation is intra-operative navigation support for the real-time reproduction of the virtually planned surgical intervention, with the goal of increased precision of the planned intervention. Such a navigation support consisting of an optically based instrument guidance system is already in use in our hospital for open liver surgery  and MWA , and may also facilitate the intra-operative and CT-guided application of HDR-BT.
The aim of the current study is twofold: to translate the knowledge from virtual planning and evaluation of liver surgeries from pre-operative 3D imaging and intra-operative navigation support into the world of HDR-BT. The goal is to investigate the feasibility and accuracy of a navigation support for the placement of brachytherapy needles for liver HDR-BT in a phantom, simulating liver metastases with copper wires. In a second step, we evaluate how to translate the yielded accuracy results from the phantom study into a clinical setting, along with the clinical exploration of such an approach based on HDR-BT plans.
Materials and methods
Experiments carried out in this work are twofold and consist of the investigation (1) of the feasibility of using a previously available stereotactic image-guidance system for CT-based interventions for the placement of HDR-BT applicators in a realistic phantom in which liver metastases were mimicked using copper wires. We have measured the accuracy of navigated needle placement and compared it with the accuracy of historical experience of free-hand needle placement in a phantom and translated these results into a clinical setting. Subsequently, (2) we have retrospectively created HDR-BT plans of patients with colorectal liver metastasis by taking the measurement results from the phantom experiment into account to explore what impact a potential inaccuracy of the needle placement with a navigation system would have on HDR-BT dosimetry.
Feasibility of image-guided HDR-BT placement
Image-guided placement of HDR-BT applicators
In the first step of the evaluation, a planning target volume (PTV) containing one of the copper wires was manually delineated in the CT data.
A treatment plan ensuring a PTV coverage of 97% with three needles was designed.
Up to three punctures were performed along the planned trajectories (Fig. 4).
A post-interventional control CT was acquired after needle insertion in which the position of the inserted needles was reconstructed and the actual dose to the PTV re-calculated.
Evaluation of the image guidance system
In order to evaluate the feasibility of the guidance approach, the accuracy of the system, defined as target positioning error (TPE), was assessed. It was computed for each needle as the distance between the planned and the achieved needle tip position. TPE was separated into a lateral component (along the needle trajectory) and the angular component. The overall accuracy of the approach was also investigated by computing the dose delivered to the PTV and comparing it to the intended dose.
Retrospective suitability assessment for HDR-BT
Description of the selected study group
No. of lesions
Location of Lesions
Segments IV, V
Segments III, IV, VII, VIII
Segments V, VI, VII, VIII
Segments III, IV, VII
HDR-BT treatment planning
For the selected patients, HDR-BT plans were generated within the treatment planning system Masterplan v4.1 (Nucletron, Elekta AB, Stockholm, Sweden). Contouring and 3D dose optimization were performed on patients’ pre-interventional CT datasets with slice thicknesses of 1 mm. For each patient, gross target volumes (GTV) were defined and manually contoured. From each GTV, a clinical target volume (CTV) was created by adding a 0.5 mm margin. Since the setup errors in brachytherapy can be assumed to be negligible, CTV corresponds to PTV. In general, for PTVs up to a diameter of 2 cm, one applicator was used, while for PTVs larger than 2 cm, two to three applicators were employed to improve conformity of the dose distribution. Dwell positions and weights of each applicator were modified until dose–volume constraints were optimally achieved. Prescription dose (PD) of the CT plans was 20 Gy, with the dosimetric goal to cover at least 90% of the PTV with the PD (V100% PTV ≥ 90%). For the resulting treatment plans, dose–volume histogram (DVH) parameters for PTV and OARs were evaluated.
Feasibility of image guidance
Suitability of treatment planning
Over the five selected patient plans, 13 PTVs ranging between 2.2 cm3 and 65.3 cm3 were contoured. The average coverage (V100%) of the 13 PTVs was 94.2 ± 2.9%. For a PD of 20 Gy per fraction, an average median dose of 2.8 ± 1.1 Gy to the normal liver (Liver-PTV) was calculated. For the same PD and a typical source strength of 4 x 104 cGy x cm2/h, the total treatment times last between 8 and 32 min.
Over the five patient plans, the conformal index (COIN) according to  was 0.55 ± 0.03.
Discussion and conclusion
General surgical stereotactic systems have been known since the early 1990s and enable surgeons to virtually plan and evaluate surgical strategies prior to the actual surgery using the available imaging data from CT or MR imaging. Immobile skeletal structures such as the rigid neurocranium provided the optimal setting for precise image guidance. Therefore, initial experiences with computer-assisted and image-guided surgery were mainly gained from rigid structures and applied in neurosurgery, complex craniofacial surgery, and orthopedic surgery . In contrast, the liver parenchyma is exposed to constant breathing motion and organ deformation. Only more recently for HPB surgery have first image guidance systems taken the complexity of the liver itself into account to a sufficient level to permit their application in daily clinical practice [38, 39]. Nevertheless, bridging the gap between virtual pre-operative intervention planning and intra-operative navigation support for the real-time reproduction of the virtually planned intervention remains a challenge. Deformations of the liver of up to 20 mm have been detected when compared to a pre-operatively acquired 3D tomographic image . Thus, the fundamental challenge in image guidance in liver interventions is a correct and real-time referencing of the pre-operatively acquired image data (3D- and 4D-/contrast-enhanced/CT or MRI) with the actual intra-operative situation. Such a navigational support of an optically based instrument guidance system is already in use in our hospital for open liver surgery  and MWA . Currently, such image-guided navigation systems are not used for the placement of applicators for liver HDR-BT. In the present study, we demonstrate the potential use of this available image-guidance technology for interventional procedures with specific adaptions to accommodate the placement of HDR-BT applicators.
In clinical practice, several possibilities exist to overcome these uncertainties. Using more than one applicator for a liver brachytherapy plan enables better coverage of complex-shaped tumor volumes, as well as better protection of the healthy surrounding tissue with its rapid dose fall-off outside the target lesion. It also increases the robustness of the plan. Additionally, the non-optimal placement of the brachytherapy needle can be compensated by a corresponding adjustment of the dwell time of the source within the target volume. With these various adjustable elements for planning, the minimum target dose at the tumor border can be achieved with no compromise in target coverage. Since the goal in liver brachytherapy is to cause necrosis in the tumor, dose heterogeneity within the target volume is of no concern and no maximum dose limit exists [27, 32].
The assessment of the present datasets indicates the feasibility of navigated intra-operative HDR-BT. The method is potentially feasible for all these patients with either a hepatic tumor load below 40% of the total liver volume or less than six liver metastases larger than 4 cm. For the selected datasets, acceptable doses to the normal liver as well as acceptable treatment times have been observed. The risk of harming blood vessels by placing applicators in liver brachytherapy is potentially mitigated through the use of the described guidance method by reducing the need for re-placement due to inaccuracy.
In clinical practice we often face complex settings in patients with CRC hepatic metastases, such as multiple, synchronous, bi-lobar, and large hepatic lesions that are located near critical structures or blood vessels. Combining this navigation-guided intraoperative HDR-BT with surgery and MWA also opens new opportunities for a combined treatment approach at the same time. Such a computer-navigated system may facilitate the application of HDR-BT for the placement of BT applicators and planning of liver HDR-BT also in situations where HDR-BT was not initially planned to be part of the intervention.
With regards to the dose prescription, in the present study we prescribed 20 Gy to at least 90% of the PTV. Previous studies of intraoperative brachytherapy for liver cancers proposed that tumor-enclosing isodoses of 15 to 30 Gy should be used [20, 21, 22, 28]. In a prospective randomized trial of 73 patients with 199 colorectal liver metastases, Ricke et al.  evaluated the minimal dose levels enclosing the CTV of 15, 20, and 25 Gy. They found a dose dependency for local control if the minimum dose in the target exceeded 20.4 Gy. In a multivariate analysis, lesion size (range of tumors 1–13.5 cm) had no impact on local control. However, in tumors larger than 8 cm, excessive irradiation time and unpredictable risks aggravated the delivery of >20 Gy in a single fraction. Nevertheless, these data show that lesions up to a diameter of 8 cm can be safely treated with a single fraction of 20 Gy applied by HDR-BT.
There are several limitations to this feasibility study. First, any conclusions revealed here are hypothesis-generating and, as such, will need to be validated within a prospective study. Several open questions for intraoperative navigation-guided HDR-BT remain: it is unclear how many applicators need to be placed for lesions > 8 cm and what conformity should be achieved, especially in bigger lesions. With only one applicator, dose conformity might be too low. More applicators might provide a better conformity of dose distribution. We suggest the number of applicators should depend on the size of the lesion. Also, dose constraints for liver HDR-BT are unclear. In their studies, Ricke et al.  used a maximum dose exposure of 5 Gy to maximally two thirds of the liver volume as a liver constraint. In their 2005 published study  on dose–response relationship for small volumes of liver parenchyma after single-fraction HDR irradiation, they used, after brachytherapy, a hepatocyte-specific contrast agent media uptake (Gd-BOPTA) for liver MRI as a surrogate for liver function. They found that the lowest threshold dose to impair hepatocyte function was 9.9 Gy (standard deviation 2.3 Gy) at 6 weeks after irradiation with repair ongoing until 3 months. After single-fraction stereotactic body radiotherapy (SBRT) to liver malignancies, Herfarth et al.  observed a focal reaction after contrast CT at a dose minimum of 13.7 Gy (range 8.9–19.2), which is consistent with the experience in brachytherapy. In the current study, we have used the dose constraints for stereotactic body radiation therapy (SBRT) according to Grimm et al. , with which technique also high doses of single fractions can be applied .
Since the technology of this system was initially developed for intra-operative support of liver resection and MWA, we have used this clinical setting to evaluate the potential benefit of the use of such a navigation system for liver BT. However, the use of this stereotactic navigation system opens also new opportunities for the placement of HDR-BT applicators within the liver by percutaneous CT guidance in patients with large, centrally localized liver metastases where no resection or MWA intervention is indicated. It may provide support in pre-interventional treatment planning (i.e., needle path, multi-applicator configuration) and applicator placement (i.e., angle and depth guidance).
In conclusion, we provide evidence for the technical feasibility of navigation-guided intra-operative HDR-BT and propose a set of inclusion criteria for clinical testing.
Compliance with ethical guidelines
Conflict of interest
E. Herrmann, D. Terribilini, P. Manser, M.K. Fix, G. Toporek, D.M. Aebersold, and K. Loessl declare that they have no competing interests. D. Candinas and S. Weber are co-founders of CAScination.
This article does not contain any studies with animal or human subjects. The study was planned and conducted in accordance with the principles of the Declaration of Helsinki of 1975 (in its most recently amended version). The protocol was approved by the ethics committee of the participating site (project ID: 2017-01447). Written informed consent was obtained from all patients.
- 9.White TJ, Roy-Choudhury SH, Breen DJ, Cast J, Maraveyas A, Smyth EF, Hartley JE, Monson JR (2004) Percutaneous radiofrequency ablation of colorectal hepatic metastases—initial experience. An adjunct technique to systemic chemotherapy for those with inoperable colorectal hepatic metastases. Dig Surg 21(4):314–320CrossRefGoogle Scholar
- 12.Collettini F, Schnapauff D, Poellinger A, Denecke T, Schott E, Berg T, Wust P, Hamm B, Gebauer B (2012) Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5–7 cm) and very large (〉7 cm) tumours. Eur Radiol 22(5):1101–1109CrossRefGoogle Scholar
- 13.Galandi D, Antes G (2004) Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev 2:CD003046.Google Scholar
- 18.Tschannen M, Toporek G, Wallach D, Peterhans M, Weber S (2012) Single Marker Localization for Automatic Patient Registration in Interventional Radiology. In: Annual Conference of the German Society for Computer and Robot assisted Surgery (CURAC) Düsseldorf, 15–16 November 2012. https://www.curac.org/images/advportfoliopro/images/CURAC2012/Tagungsband_CURAC2012.pdf
- 26.Witthauer L (2014) Dosimetric Impact of Geometric Uncertainties in Navigated HDR-Brachytherapy for Liver Tumours, Master Thesis ETH ZurichGoogle Scholar
- 31.Grimm J, LaCouture T, Croce R, Yeo I, Zhu Y, Xue J (2011) Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. J Appl Clin Med Phys 8(12(2)):3368Google Scholar
- 37.MeVis Distant Service AG, Bremen, Germany https://www.mevis.de
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.